Akero Therapeutics Inc (NASDAQ: AKRO) is 38.39% higher on its value in year-to-date trading and has touched a low of $17.86 and a high of $58.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKRO stock was last observed hovering at around $37.67 in the last trading session, with the day’s gains setting it 0.83%.
Currently trading at $38.50, the stock is -0.95% and -11.75% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 2.20% at the moment leaves the stock 15.88% off its SMA200. AKRO registered 87.71% gain for a year compared to 6-month gain of 24.92%. The firm has a 50-day simple moving average (SMA 50) of $43.6237 and a 200-day simple moving average (SMA200) of $33.2232.
The stock witnessed a -14.86% loss in the last 1 month and extending the period to 3 months gives it a 50.39%, and is 2.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.42% over the week and 7.44% over the month.
Akero Therapeutics Inc (AKRO) has around 63 employees, a market worth around $3.07B and $0.00M in sales. Distance from 52-week low is 115.57% and -34.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.07%).
The EPS is expected to shrink by -14.49% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Akero Therapeutics Inc (AKRO) Top Institutional Holders
271.0 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 96.41% of the company’s shares. The shares outstanding are 72.38M, and float is at 70.71M with Short Float at 7.76%. Institutions hold 94.19% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 6.88 million shares valued at $161.28 million. The investor’s holdings represent 9.9425% of the AKRO Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.59 million shares valued at $131.06 million to account for 8.0778 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.43 million shares representing 7.8542% and valued at over $127.43 million, while GENERAL ATLANTIC, L.P. holds 7.5679 of the shares totaling 5.23 million with a market value of $122.79 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Yale Catriona, the company’s Chief Development Officer. SEC filings show that Yale Catriona sold 9,073 shares of the company’s common stock on Apr 15 ’25 at a price of $37.91 per share for a total of $0.34 million. Following the sale, the insider now owns 95034.0 shares.
Akero Therapeutics Inc disclosed in a document filed with the SEC on Apr 10 ’25 that Cheng Andrew (President and CEO) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Apr 10 ’25 and was made at $35.23 per share for $1.06 million. Following the transaction, the insider now directly holds 0.62 million shares of the AKRO stock.
Still, SEC filings show that on Apr 07 ’25, Rolph Timothy (Chief Scientific Officer) disposed off 6,250 shares at an average price of $35.88 for $0.22 million. The insider now directly holds 169,721 shares of Akero Therapeutics Inc (AKRO).
